Page 95 - Clinical Development News Today

Bengaluru, Aug 4 (IANS) Biocon Biologics, a subsidiary of pharmaceutical giant Biocon Ltd, has made several key leadership appointments which will play an

Biocon Biologics, a subsidiary of pharmaceutical giant Biocon Ltd, has made several key leadership appointments which will play an important role in transforming the organisation and realising its ambition of building a global biosimilars ...

BURLINGTON, Mass., August 04, 2023--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced the publication of a cost-effectiveness analysis of ropeginterferon alfa-2b-njft (marketed as BESREMi®) in the Journal of Comparative Effectiveness Research. The analysis, titled "Cost-...

Analysis published in the Journal of Comparative Effectiveness Research shows ropeginterferon alfa-2b-njft provided a cost-effective benefit in quality-adjusted life years compared to a commonly used treatment pathwayBURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia C...

Scientists at a major US hospital have developed a ‘cancer-killing pill’ that appears to ‘annihilate’ solid tumors through targeted chemotherapy.

/PRNewswire/ -- Complement Therapeutics GmbH (CTx), a preclinical stage biotechnology company developing novel therapeutics for complement-mediated diseases,...

OSP had the pleasure of speaking to TransCelerate Biopharma's new CEO, Janice Chang, at this year's DIA.

03.08.2023 - Regulatory approval received in New Zealand to advance AB-101, our oral PD-L1 inhibitor, into a Phase 1 clinical trial with dosing to begin this quarter AB-729 (imdusiran), in combination with pegylated interferon alfa-2a, in a Phase ...

At-risk families of patients diagnosed with motor neurone disease (MND), better known in the US as amyotrophic lateral sclerosis (ALS) will now have access to genetic sequencing thanks to a financial award from Innovate UK.

/PRNewswire/ -- Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Oncology, Inc., announced today the launch of the REZILIENT3 trial...